Title:Challenges in Immunomodulation for Psoriasis: Recent Advancements and
Need of Therapies
Volume: 19
Issue: 3
Author(s): Dilpreet Singh*
Affiliation:
- University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali (140413), India
Keywords:
Psoriasis, immunomodulation, biologics, interleukins, small molecules, janus kinases, cytokines, therapy, treatment resistance, personalized medicine.
Abstract: Psoriasis is a chronic immune-mediated skin disorder affecting millions worldwide. The
pathogenesis of psoriasis involves dysregulated immune responses characterized by aberrant activation
of T cells and proinflammatory cytokines. Immunomodulation has emerged as a promising therapeutic
approach for managing psoriasis, aiming to restore immune homeostasis. However, despite
significant advancements, challenges persist in developing effective immunomodulatory therapies.
This abstract reviews recent developments in psoriasis immunomodulation, encompassing novel targets
and therapeutic modalities. Advances in biologics targeting interleukins (IL) and their receptors,
such as IL-17, IL-23, and IL-12/23, have demonstrated substantial clinical efficacy. Additionally,
small molecules that inhibit Janus kinases (JAK) and phosphodiesterase 4 (PDE4) have shown promise
in regulating immune responses. Despite these advancements, certain limitations hinder the success
of immunomodulatory therapies. Treatment resistance, safety concerns, and high costs remain
critical challenges. Furthermore, a deeper understanding of the complex immunopathogenesis of psoriasis
is essential for developing targeted and personalized therapies. In conclusion, immunomodulation
has revolutionized the management of psoriasis, offering remarkable improvements in patient
outcomes. Continued research and innovative therapeutic strategies are needed to overcome current
challenges and pave the way for more efficient, safe, and accessible treatments for psoriasis.
